A brand new cancer research project named Breast Cancer Risk Assessment in Young Women (BCAN-RAY), in memory of Sarah Harding, has officially begun with first woman taking part
A brand new cancer research project has officially begun in memory of Girls Aloud’s Sarah Harding, with the first woman already taking part.
The new Breast Cancer Risk Assessment in Young Women project will become one of the first in the world to identify which women are at risk of getting the disease in their 30s.Sarah sadly passed away in September 2021, and it was later revealed that one of the singer’s last wishes was for there to be another method of identifying early stages of breast cancer, in the hopes of saving lives.
Catherine continued: “Hopefully it will have massive implications and will improve the way we screen younger women.”
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
New model could offer personalised breast cancer screening approach, say expertsResearchers say their study could help to potentially reduce breast cancer deaths, and cut unnecessary screenings for those at lower risk.
Lire la suite »
New model could offer personalised breast cancer screening approach, say expertsResearchers say their study could help to potentially reduce breast cancer deaths, and cut unnecessary screenings for those at lower risk.
Lire la suite »
Swedish study changes national guidelines for genetic testing in breast cancerBRCA1 and BRCA2 are well-known breast cancer genes associated with a significantly increased risk of hereditary breast and ovarian cancer. However, there are an additional eleven genes associated with elevated risk for these types of cancer.
Lire la suite »
Personalised breast cancer screening could show death riskResearchers say breast cancer screening is vital, reducing deaths, but can sometimes detect tumours that are not harmful, which leads to unnecessary treatments
Lire la suite »
Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancerA novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.
Lire la suite »
New model predicts 10-year breast cancer riskA team of researchers at the University of Oxford, led by the Nuffield Department of Primary Care Health Sciences, have developed a new model that reliably predicts a woman's likelihood of developing and then dying of breast cancer within a decade.
Lire la suite »